Cart
sales@molnova.com
Gefitinib analog III
CAS No. 788136-89-0
Gefitinib analog III( —— )
Catalog No. M35870 CAS No. 788136-89-0
Gefitinib analog III(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate) has potential anti-inflammatory and anti-tumor activity and can be used to study its interactions and activity in organisms.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 43 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGefitinib analog III
-
NoteResearch use only, not for human use.
-
Brief DescriptionGefitinib analog III(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate) has potential anti-inflammatory and anti-tumor activity and can be used to study its interactions and activity in organisms.
-
DescriptionGefitinib analog III(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate) has potential anti-inflammatory and anti-tumor activity and can be used to study its interactions and activity in organisms.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number788136-89-0
-
Formula Weight361.76
-
Molecular FormulaC17H13ClFN3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OC(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
3-Hydroxytectorigeni...
3′-Hydroxytectorigenin-7-O-β-D-xylosyl-(1→6)-β-D-glucopyranoside is an antioxidant that can be found in Pueraria montana var. lobata. It exhibits DPPH radical scavenging activity, with an IC50 value of 42 μg/mL.
-
Katacalcin TFA
Katacalcin TFA (PDN 21 TFA) a potent plasma calcium-lowering peptide.
-
PA-8
PA-8 is a small molecule receptor antagonist for PACAP Type I (PAC1) that is selective, effective, and orally active. PA-8 inhibits PacAP-induced CREB phosphorylation at PAC1- receptors, but does not inhibit VPAC1- or vpac2 receptors.
